Symfi
Generic: efavirenz-lamivudine-tenofovir df
Tablet
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
Also known as:
SYMFI TAB
Compare Prices
Coverage by Insurer
Informational only — Coverage rules change frequently; verify tier placement and restrictions with your plan or pharmacy before acting.
Blue Cross Blue Shield Federal
3 plans| Plan | Tier | Prior Auth | Step Therapy | Quantity Limit | Restrictions |
|---|---|---|---|---|---|
|
BCBS Federal Standard Option 2026
via efavirenz-lamivudine-tenofovir df |
Tier 1 - Generic | — | — | — | None |
|
BCBS Federal Basic Option 2026
via efavirenz-lamivudine-tenofovir df |
Tier 1 - Generic | — | — | — | None |
|
BCBS Federal Focus 2026
via efavirenz-lamivudine-tenofovir df |
Tier 1 - Generic | — | — | — | None |
Blue Cross Blue Shield of NC
10 plans| Plan | Tier | Prior Auth | Step Therapy | Quantity Limit | Restrictions |
|---|---|---|---|---|---|
| BCBSNC Blue Local 2026 | Tier 2 - Medium Cost Generic/Brand | — | — | — | None |
| BCBSNC Blue Value 2026 | Tier 2 - Medium Cost Generic/Brand | — | — | — | None |
| BCBSNC Blue Care 2026 | Tier 2 - Medium Cost Generic/Brand | — | — | — | None |
| BCBSNC Blue Advantage 2026 | Tier 2 - Medium Cost Generic/Brand | — | — | — | None |
| BCBSNC Blue Home with UNC Health Alliance 2026 | Tier 2 - Medium Cost Generic/Brand | — | — | — | None |
|
BCBSNC Blue Value 2026
via Efavirenz/Lamivudine/Teno |
Tier 3 - High Cost Brand | — | — | — | None |
|
BCBSNC Blue Advantage 2026
via Efavirenz/Lamivudine/Teno |
Tier 3 - High Cost Brand | — | — | — | None |
|
BCBSNC Blue Home with UNC Health Alliance 2026
via Efavirenz/Lamivudine/Teno |
Tier 3 - High Cost Brand | — | — | — | None |
|
BCBSNC Blue Local 2026
via Efavirenz/Lamivudine/Teno |
Tier 3 - High Cost Brand | — | — | — | None |
|
BCBSNC Blue Care 2026
via Efavirenz/Lamivudine/Teno |
Tier 3 - High Cost Brand | — | — | — | None |
NC State Health Plan
6 plans| Plan | Tier | Prior Auth | Step Therapy | Quantity Limit | Restrictions |
|---|---|---|---|---|---|
|
NC State Health Plan - 80/20 Plus PPO 2026
via efavirenz-lamivudine-tenofovir df |
Tier 1 - Preferred Generic | — | — | ✓ | QL |
|
NC State Health Plan - 70/30 Standard PPO 2026
via efavirenz-lamivudine-tenofovir df |
Tier 1 - Preferred Generic | — | — | ✓ | QL |
|
NC State Health Plan - HDHP 2026
via efavirenz-lamivudine-tenofovir df |
Tier 1 - Preferred Generic | — | — | ✓ | QL |
| NC State Health Plan - 80/20 Plus PPO 2026 | Tier 3 - Non-Preferred Brand | — | — | ✓ | QL |
| NC State Health Plan - 70/30 Standard PPO 2026 | Tier 3 - Non-Preferred Brand | — | — | ✓ | QL |
| NC State Health Plan - HDHP 2026 | Tier 3 - Non-Preferred Brand | — | — | ✓ | QL |